• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

U.S. Market for Molecular Diagnostics, 2nd Edition

$3,500.00 – $7,000.00

Clear
SKU: KLI943017 Categories: Diagnostics Market Research, Molecular & Nucleic Acid Testing Pages: 626
  • Description
  • Table of Contents
  • Latest reports

Description

Molecular diagnostics are seen as being a major breakthrough in medical science. While the technology itself has broad applications to such areas as agricultural bioterrorism and environmental science, medical and medical research applications have provided the primary focus. As a result, great things have been predicted for the development and use of new therapeutics based on molecular testing approaches.

The primary molecular diagnostics approaches are based on two major database sciences (genomics and proteomics) and their relationship to disease and metabolic processes (functional genomics and functional proteomics). The genome or proteome that forms the basis for these tests is very often of human origins, but may also be from a pathogen. As a result, the breadth of application for molecular diagnostic is virtually unlimited. With all this opportunity, however, progress has been slow in the development, introduction and commercialization of molecular diagnostics. This has been related to the difficulty and expense of performing such assays, and the utility of the test procedures in the absence of substantive therapeutic options based on the additional data provided by these assays.

This study looks at the basis for molecular diagnostics in the fields of genomics and proteomics; the technologies that are used to apply genomic and proteomic data to the diagnosis of disease; the diseases and conditions that are primary and secondary targets for this technology; the economics of molecular diagnostic testing; and its potential impacts on medical practice and the diagnostics markets over the next ten years. Number of tests, market potential, and estimated cost per test is provided for each test for each of the 10 years.

Table of Contents

 

Chapter One: Executive Summary

 

  • Background
  • Scope and Methodology
  • Size and Growth of the Market
  • Competitive Picture
  • Market Trends and Factors

 

Chapter Two: Introduction

 

  • Background
  • Market Erosion
  • Clinical Relevance
  • Cost-Benefit Relationships
  • Scientific Limitations
  • Major Influencing Technologies
  • Genomics
  • Genes, Functional Genomics and Disease
  • Proteomics

 

Chapter Three: Molecular Diagnostics Technologies

 

  • Background
  • Amplification Technologies
  • Gene Amplification
  • Signal Amplification
  • Probe Technologies
  • Microchip Technologies
  • Electrophoretic Technologies
  • Blotting Technologies
  • Single Nucleotide Polymorphism (SNP) Analysis
  • Restriction Fragment Length Polymorphism (RFLP) Analysis
  • RNA Inhibition (RNAi) Analysis

 

Chapter Four: Applications of Molecular Diagnostics

 

  • The Testing Environment
  • Commercial Laboratories
  • University/Hospital Laboratories
  • Blood Banking Analysis
  • Genetic Diseases
  • Cancer
  • Pharmacogenetics
  • Infectious Disease Testing

    • Chlamydia trachomatis
    • Neisseria gonorrhoeae
    • Pneumonia
    • Human Immunodeficiency Virus (HIV)
    • Tuberculosis
    • Hepatitis B (HBV)
    • Hepatitis C (HCV)
    • Human Papillomavirus (HPV)
    • Herpes Simplex (HSV)
    • West Nile Virus (WNV)

 

Chapter Five: The Market for Molecular Diagnostics

 

  • Market Size and Trending
  • Blood Bank and Plasmapheresis Center Testing
  • Gene and Chromosome Testing
  • Oncology Testing
  • Pharmacogenetic Testing
  • Infectious Disease Testing
  • Competitive Picture and Industry Structure
  • Future Prospects

 

Chapter Six: Company Profiles

 

  • Overview
  • Abbott Diagnostics Division of Abbott Laboratories
  • Affymetrix, Inc.
  • Agilent Technologies, Inc. Division of Hewlett-Packard

  • Alnylam Pharmaceuticals
  • Ambion RNA Diagnostics Division of Ambion, Inc.
  • Applied Biosystems Group Division of Applera Corporation
  • Celera Genomics/Celera Diagnostics Division of Applera Corporation
  • Cenetron Diagnostics
  • Cenix BioScience GmbH
  • Cepheid, Inc.
  • Chiron Corporation
  • Dharmacon, Inc.
  • diaDexus, LLC
  • Digene Corporation
  • Gene Logic, Inc.
  • Gen-Probe Incorporated
  • Illumina, Inc.
  • Innogenetics NV
  • Invitrogen Corporation
  • Mirus Corporation
  • Myriad Genetics, Inc.
  • Nanogen, Inc.
  • Orchid BioSciences, Inc.
  • Perkin-Elmer Corp.
  • Roche Diagnostics Division/Roche Molecular Systems F. Hoffmann-LaRoche Ltd.
  • Sequenom Genetic Systems Division Of Sequenom
  • Sirna Therapeutics (Formerly Ribozyme Pharmaceuticals)
  • Vysis Subsidiary of Abbott Laboratories

 

Chapter Seven: Conclusions & Strategic Implications

 

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion
  • Eighth Conclusion
  • Ninth Conclusion
  • Tenth Conclusion

 

APPENDIX A: Company Names and Addresses

 

APPENDIX B: Glossary

 

List of Exhibits

 

Chapter One: Executive Summary

 

  • Table 1-1: Molecular Diagnostics Technologies
  • Table 1-2: Projected Molecular Diagnostics Market Potential in the United States by Applications Segment: 2003-2013
  • Figure 1-1: Trending in the Projected Molecular Diagnostics Market Potential in the United States by Applications Segment: 2003-2013
  • Figure 1-2: Trending in the Composition of the Projected Molecular Diagnostics Market Potential in the United States by Applications Segment: 2003-2013
  • Table 1-3: Key Active Competitors in the United States for Molecular Diagnostics Products and Technologies

 

Chapter Three: Molecular Diagnostics Technologies

 

  • Table 3-1: Molecular Diagnostics Technologies
  • Table 3-2: Gene Amplification Technologies
  • Table 3-3: Commonly Used Signal Amplification Technologies for Genetic Analysis

 

Chapter Four: Applications of Molecular Diagnostics

 

  • Table 4-1: Commercially Available Molecular Diagnostics Tests
  • Table 4-2: Key “Home-Brew” Molecular Diagnostics Assays
  • Figure 4-1a: Distribution of Molecular Diagnostics Testing in the
    United States: 2004
  • Table 4-3: Projected Blood Banking and Plasmapheresis Testing by Molecular Diagnostics in the United States: 2003-2013
  • Figure 4-1: Trending in the Projected Number of Blood Banking and Plasmapheresis Tests by Molecular Diagnostics in the United States: 2003-2013
  • Figure 4-2: Trending in the Percentage Distribution of Blood Banking and Plasmapheresis Tests by Molecular Diagnostics in the United States: 2003-2013
  • Table 4-4: Commercially Available Molecular (Nucleic Acid) Tests for Blood,
    Plasma and Organ Donor Screening in the United States: 2004
  • Table 4-5: Key Hereditary Diseases
  • Table 4-6: Projected Genetic Disease Testing by Molecular Diagnostics in the
    United States: 2003-2013
  • Figure 4-3: Trending in the Projected Number of Genetic Disease Tests by Molecular Diagnostics in the United States: 2003-2013
  • Figure 4-4: Trending in the Percentage Distribution of Genetic Disease Tests by Molecular Diagnostics in the United States: 2003-2013
  • Table 4-7: Projected Oncology Testing by Molecular Diagnostics in the United
    States: 2003-2013
  • Figure 4-5: Trending in the Projected Number of Oncology Tests by Molecular Diagnostics in the United States: 2003-2013
  • Figure 4-6: Trending in the Percentage Distribution of Oncology Tests by Molecular Diagnostics in the United States: 2003-2013
  • Table 4-8: Drugs Affected by the Cytochrome p450 System
  • Table 4-9: Projected Pharmacogenetic Testing by Molecular Diagnostics in the
    United States: 2003-2013
  • Figure 4-7: Trending in the Projected Number of Pharmacogenetic Tests by
    Molecular Diagnostics in the United States: 2003-2013
  • Figure 4-8: Trending in the Percentage Distribution of Pharmacogenetic Tests by Molecular Diagnostics in the United States: 2003-2013
  • Table 4-10: Projected Infectious Disease Testing by Molecular Diagnostics in the
    United States: 2003-2013

 

Chapter Five: The Market for Molecular Diagnostics

 

  • Table 5-1: Projected Molecular Diagnostics Market Potential in the United
    States by Applications Segment: 2003-2013 ($Millions)
  • Figure 5-1: Trending in the Projected Molecular Diagnostics Market
    Potential in the United States by Applications Segment: 2003-2013
  • Figure 5-2: Composition of the Projected Molecular Diagnostics Market
    Potential in the United States by Applications Segment: 2003-2013
  • Table 5-2: Projected Molecular Diagnostics Market Potential in the United
    States by Application Segment – Detailed Analysis: 2003 – 2013
  • Figure 5-3: Trending in the Projected Molecular Diagnostics Test Volume
    Potential in the United States by Applications Segment: 2003-2013
  • Figure 5-4: Composition of the Projected Molecular Diagnostics Test Volume
    Potential in the United States by Applications Segment: 2003-2013
  • Figure 5-5: Trending in the Projected Molecular Diagnostics Average Cost Per
    Test in the United States by Applications Segment: 2003-2013
  • Table 5-3: Projected Blood Banking and Plasmapheresis Molecular Diagnostics
    Testing Market Potential in the United States: 2003-2013
  • Figure 5-6: Trending in the Projected Test Volume for Molecular Diagnostics in
    Blood Banking Applications in the United States: 2003-2013
  • Figure 5-7: Trending in the Projected Test Volume Composition for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
  • Figure 5-8: Trending in the Projected Market Potential for Molecular Diagnostics in Blood Banking Applications in the United States: 2003-2013
  • Figure 5-9: Trending in the Projected Market Potential Composition for
    Molecular Diagnostics in Blood Banking Applications in the
    United States: 2003-2013
  • Figure 5-10: Trending in the Projected Average Cost Per Test for Molecular
    Diagnostics in Blood Banking Applications in the United States: 2003-2013
  • Table 5-4: Projected Gene and Chromosome Molecular Diagnostics Testing
    Market Potential in the United States: 2003-2013
  • Figure 5-11: Trending in the Projected Test Volume for Molecular Diagnostics in
    Gene and Chromosome Testing in the United States: 2003-2013
  • Figure 5-12: Trending in the Projected Test Volume Composition for Molecular Diagnostics in Gene and Chromosome Testing in the United States: 2003-2013
  • Figure 5-13: Trending in the Projected Market Potential for Molecular
    Diagnostics in Gene and Chromosome Testing in the United States: 2003-2013
  • Figure 5-14: Trending in the Projected Market Potential Composition for
    Molecular Diagnostics in Gene and Chromosome Testing in the United
    States: 2003-2013
  • Figure 5-15: Trending in the Projected Average Cost Per Test for Molecular
    Diagnostics in Gene and Chromosome Testing in the United States: 2003-2013
  • Table 5-5: Projected Molecular Diagnostics Oncology Testing Market
    Potential in the United States: 2003-2013
  • Figure 5-16: Trending in the Projected Test Volume for Molecular Diagnostics in Oncology Testing in the United States: 2003-2013
  • Figure 5-17: Trending in the Projected Test Volume Composition for Molecular Diagnostics in Oncology Testing in the United States: 2003-2013
  • Figure 5-18: Trending in the Projected Market Potential for Molecular
    Diagnostics in Oncology Testing in the United States: 2003-2013
  • Figure 5-19: Trending in the Projected Market Potential Composition for
    Molecular Diagnostics in Oncology Testing in the United States: 2003-2013
  • Figure 5-20: Trending in the Projected Average Cost Per Test for Molecular
    Diagnostics in Oncology Testing in the United States: 2003-2013
  • Table 5-6: Projected Molecular Diagnostics Pharmacogenetic Testing Market
    Potential in the United States: 2003-2013
  • Figure 5-21: Trending in the Projected Test Volume for Molecular Diagnostics in Pharmacogenetic Testing in the United States: 2003-2013
  • Figure 5-22: Trending in the Projected Test Volume Composition for Molecular Diagnostics in Pharmacogenetic Testing in the United States: 2003-2013
  • Figure 5-23: Trending in the Projected Market Potential for Molecular
    Diagnostics in Pharmacogenetic Testing in the United States: 2003-2013
  • Figure 5-24: Trending in the Projected Market Potential Composition for
    Molecular Diagnostics in Pharmacogenetic Testing in the United
    States: 2003-2013
  • Figure 5-25: Trending in the Projected Average Cost Per Test for Molecular
    Diagnostics in Pharmacogenetic Testing in the United States: 2003-2013
  • Table 5-7: Projected Molecular Diagnostics Infectious Disease Testing Market
    Potential in the United States: 2003-2013
  • Figure 5-26: Trending in the Projected Test Volume for Molecular Diagnostics in Infectious Disease Testing in the United States: 2003-2013
  • Figure 5-27: Trending in the Projected Test Volume for Molecular Diagnostics in Infectious Disease Testing in the United States: 2003-2013
  • Figure 5-28: Trending in the Projected Market Potential for Molecular
    Diagnostics in Infectious Disease Testing in the United States: 2003-2013
  • Figure 5-29: Trending in the Projected Market Potential Composition for
    Molecular Diagnostics in Infectious Disease Testing in the United
    States: 2003-2013
  • Figure 5-30: Trending in the Projected Average Cost Per Test (ECPT) for
    Molecular Diagnostics in Infectious Disease Testing in the United
    States: 2003-2013
  • Table 5-8: Key Active Competitors in the United States for Molecular
    Diagnostics Products and Technologies

 

    Global Immunoassay Market: Trends, Technologies, and Growth Opportunities, 2025
    June 12, 2025
    Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 12th Edition
    May 13, 2025
    In Vitro Diagnostic (IVD) Trends and Market Update, 2025
    April 7, 2025
    In Vitro Diagnostics Business Outlook, 2025 (6 Issues)
    April 3, 2025

Related products

  • Placeholder image

    Molecular Diagnostics for Infectious Disease Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00
  • Placeholder image

    Medical Imaging Markets, Volume III – Ultrasound

    $1,200.00 – $5,990.00
  • Placeholder image

    Cell-Based Diagnostics: Technology, Applications, and Markets

    $3,500.00 – $7,000.00
  • Placeholder image

    Molecular Diagnostics for Inherited Disease Testing: Testing volume, cost per test, and market potential

    $995.00 – $1,990.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
The U.S. Market for Interventional Radiology ProductsEarly Stage Drug Discovery 2004: Combi-chem & High Throughput Screening...
Scroll to top